[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334334-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334334-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-phase-iii-enrgy-trial-zenocutuzumab-in-patients-with-cancers-harboring-nrg1-gene-fusions","The phase I/II eNRGy trial - Zenocutuzumab in patients with cancers harboring NRG1 gene fusions","","Neuregulin 1 (NRG1) gene fusions act as oncogenic drivers in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and other solid tumors, but occur in less than 1% of solid cancers and leave patients with limited treatment options. The phase II component of the eNRGy open-label multicenter phase I/II trial evaluates zenocutuzumab, a bispecific IgG1 antibody targeting HER2 and HER3 and blocking NRG1 binding via a Dock & Block mechanism. The study assesses safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity, including a primary endpoint requiring tumor size reduction of at least 30%.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-phase-iii-enrgy-trial-zenocutuzumab-in-patients-with-cancers-harboring-nrg1-gene-fusions/334334/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-phase-iii-enrgy-trial-zenocutuzumab-in-patients-with-cancers-harboring-nrg1-gene-fusions/334334.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What cancers are included in the eNRGy trial?","Question",{"text":63,"@type":64},"Patients with NRG1 gene-fusion positive cancers are included, including non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and other solid tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does zenocutuzumab work in this trial?",{"text":68,"@type":64},"Zenocutuzumab is a bispecific IgG1 antibody that targets both HER2 and HER3 and inhibits NRG1 binding through a Dock & Block mechanism of action.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the primary endpoint of the eNRGy trial?",{"text":72,"@type":64},"The primary end point is the percentage of patients whose tumors decrease in size by 30% or more.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334334,1790378144,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Clinical Trial Protocol  \nThe phase I/II eNRGy trial: Zenocutuzumabin patients with cancers harboring NRG1 gene fusions  \nDong-Wan Kim*,‡,1 , Alison M Schram‡,2, Antoine Hollebecque3, Kazumi Nishino4 , Teresa Macarulla5, Sun Young Rha6, Michal Duruisseaux7,8,9, Stephen V Liu10 , Mohammed Najeeb Al Hallak11, Kumiko Umemoto12, Claas Wesseler13, James M Cleary14,15 , Christoph Springfeld16, Cindy Neuzillet17, Andrew Joe18, Shekeab Jauhari18, Jim Ford19 & Koichi Goto20  \n1 Department of Internal Medicine, Seoul National University College of Medicine & Seoul National University Hospital, Seoul, 03080, Republic of Korea  \n2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n3 Drug Development (DITEP), GI Oncology, Gustave Roussy Cancer Campus, Villejuif, 94805, France  \n4 Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 540-0008, Japan  \n5 Gastrointestinal and Endocrine Tumor Unit, Vall d´Hebrn University Hospital, Vall d´Hebrn Institute of Oncology (VHIO), Barcelona, 08035, Spain  \n6 Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, 03722, Republic of Korea  \n7 Department of Respiratory Medicine and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, 69500, France  \n8 Cancer Research Centre of Lyon, UMR INSERM 1052 CNRS 5286, Lyon, 69008, France  \n9 Claude Bernard University Lyon 1, University of Lyon, Villeurbanne, 69100, France  \n10Thoracic Oncology and Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, WA 20007, USA  \n11 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA  \n12 Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan  \n13 Department of Pulmonology, Asklepios Tumorzentrum Hamburg, Klinikum Harburg, Hamburg, 21075, Germany  \n14 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA  \n15 Harvard Medical School, Boston, MA 02215, USA  \n16 Department of Medical Oncology, Heidelberg University Hospital, Department of Medical Oncology, Heidelberg, 69120, Germany  \n17 GI Oncology, Medical Oncology Department, Curie Institute, Versailles-Saint Quentin University, Saint-Cloud, 92064, France  \n18 Clinical Development, Merus NV, Utrecht, 3584, The Netherlands  \n19 Clinical Trials, Merus NV, Utrecht, 3584, The Netherlands  \n20 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan  \n*Author for correspondence: Tel.: +82 2 2072 2995; [kimdw@snu.ac.kr](kimdw@snu.ac.kr)[ ](kimdw@snu.ac.kr)‡Authors contributed equally  \nNeuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1 fusions are rare, occurring in less than 1% of solid tumors. Patients with NRG1 fusion positive (NRG1+) cancer have limited therapeutic options. Zenocutuzumab is a novel, bispecific IgG1 antibody that targets both HER2 and HER3 proteins and inhibits NRG1 binding through a ‘Dock & Block􀀂R ’ mechanism of action. Here, we describe the rationale and design of the phase II component of the eNRGy trial, part of the overall, open-label phase I/II, multicenter trial exploring the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of zenocutuzumab in patients with NRG1+ NSCLC, PDAC or other solid tumors.  \nPlain language summary – eNRGy: a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions: NRG1 gene fusions are rare mutations that cause cancer cells to grow. These fusions are found in many different types of cancer. Tumors with NRG1 gene fusions do not respond well to standard treatment options. Zenocutuzumab, or Zeno, is a treatment that is being tested to see if it can stop cancer that is growing because of ","cbCain2C0ZF0VUnn","https://ap.wps.com/l/cbCain2C0ZF0VUnn","pdf",3121378,11,"English","# Clinical Trial Protocol\n## eNRGy trial rationale and design\n## Trial objectives and endpoints\n## Study population and treatment schedule\n## Investigational mechanism and target biology\n## Trial recruitment and reference information","[{\"question\":\"What cancers are included in the eNRGy trial?\",\"answer\":\"Patients with NRG1 gene-fusion positive cancers are included, including non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and other solid tumors.\"},{\"question\":\"How does zenocutuzumab work in this trial?\",\"answer\":\"Zenocutuzumab is a bispecific IgG1 antibody that targets both HER2 and HER3 and inhibits NRG1 binding through a Dock \\u0026 Block mechanism of action.\"},{\"question\":\"What is the primary endpoint of the eNRGy trial?\",\"answer\":\"The primary end point is the percentage of patients whose tumors decrease in size by 30% or more.\"}]","The phase I/II eNRGy trial - Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | PDF",1790006291,28]